1. Home
  2. WIMI vs NEUP Comparison

WIMI vs NEUP Comparison

Compare WIMI & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo WiMi Hologram Cloud Inc.

WIMI

WiMi Hologram Cloud Inc.

HOLD

Current Price

$1.64

Market Cap

32.0M

Sector

Technology

ML Signal

HOLD

NEUP

Neuphoria Therapeutics Inc.

N/A

Current Price

$4.44

Market Cap

28.7M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
WIMI
NEUP
Founded
2015
1996
Country
China
United States
Employees
N/A
8
Industry
Computer Software: Prepackaged Software
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
32.0M
28.7M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
WIMI
NEUP
Price
$1.64
$4.44
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$21.00
AVG Volume (30 Days)
171.6K
58.4K
Earning Date
04-24-2026
05-23-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$1.24
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.46
$3.65
52 Week High
$5.65
$21.31

Technical Indicators

Market Signals
Indicator
WIMI
NEUP
Relative Strength Index (RSI) 50.84 36.19
Support Level $1.58 $3.91
Resistance Level $2.06 $4.56
Average True Range (ATR) 0.11 0.31
MACD 0.00 -0.09
Stochastic Oscillator 48.28 6.83

Price Performance

Historical Comparison
WIMI
NEUP

About WIMI WiMi Hologram Cloud Inc.

WiMi Hologram Cloud Inc and its subsidiaries offer augmented reality (AR) based holographic services and products to cater to its customers. Its AR service and product offerings consist of holographic AR advertising services and holographic AR entertainment products. It is also into the semiconductor business, in which the company provides central processing algorithm services and computer chip products to enterprise customers and the sales of comprehensive solutions for central processing algorithms and related services with software and hardware integration. The company reports in three segments: AR advertising, AR entertainment, and Semiconductor. Its geographical segments are Mainland China, Hong Kong, and International.

About NEUP Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.

Share on Social Networks: